Summary
The product HEXOS 75 mg/ml, manufactured by Driada Medical, underwent laboratory testing to confirm its composition and dosage accuracy. The analysis, performed by Janoshik Analytical, identified the active ingredient as trenbolone hexahydrobenzylcarbonate, with a measured concentration of 71.87 mg/ml, slightly below the labeled claim of 75 mg/ml. This results in a variance of 4.17% below specification, which is within acceptable limits.
Testing commenced on 6 January 2022, with the sample received on 7 January 2022, and the analysis finalized on 9 January 2022. The product was submitted and funded by Driada Medical, emphasizing the need for careful interpretation of the findings. This report aims to provide transparency and support harm reduction efforts for consumers.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: HEXOS 75 mg/ml
- Active Ingredient: Trenbolone Hexahydrobenzylcarbonate
- Batch Number: 123725
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #16170
- Testing Ordered: 6 January 2022
- Sample Received: 7 January 2022
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 75 mg/ml (as stated on the label)
- Measured Concentration: 71.87 mg/ml
- Accuracy: 95.83% (4.17% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/16170_REZLLI7CN4ET
- Originally Published: https://thinksteroids.com/community/posts/2983012/
Evaluation of Manufacturer-Funded Testing
Since the product testing was both submitted and funded by the manufacturer, Driada Medical, it is essential to interpret the results critically. The analysis shows accurate dosing within a reasonable margin of error. Janoshik Analytical’s reputation for unbiased and reliable testing enhances the credibility of the results.
Conclusion
The testing of HEXOS 75 mg/ml confirms its composition and potency, with a measured concentration that is slightly below the labeled claim but within acceptable accuracy standards. This supports harm reduction and transparency in the anabolic steroid market. Manufacturer-funded reports like this are a valuable resource for consumers when interpreted alongside independent findings.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside independent results. Readers are encouraged to interpret this information responsibly.
